STAGE II LUNG CANCER AJCC V8

This large, late-stage trial is testing whether adding an immunotherapy drug (atezolizumab) to a highly targeted form of radiation therapy works better than radiation alone. It is for people with early-stage, non-small cell lung cancer who cannot have surgery. The main goal is to…

This large, late-stage trial is testing whether adding an immunotherapy drug (atezolizumab) to the standard treatment of chemotherapy and radiation helps people with limited-stage small cell lung cancer live longer. About 544 participants are randomly assigned to receive either t…

This large, late-stage trial is testing if adding a new oral drug (AZD6738) to an existing immunotherapy (durvalumab) works better than the immunotherapy alone to keep non-small cell lung cancer from coming back. It is for patients who have already had chemotherapy and surgery to…

This early-stage study is testing a new nanoparticle drug called NBTXR3 for people with inoperable, recurrent non-small cell lung cancer. The nanoparticle is injected directly into the tumor and is designed to make standard radiation therapy more powerful at killing cancer cells,…

This study is testing a two-part treatment for patients with stage II or III non-small cell lung cancer who are not candidates for surgery or standard chemo-radiation. First, patients receive a shorter, more intense course of radiation over three weeks. Then, they receive an immu…

This study is testing whether a lung cancer immunotherapy drug can be safely and effectively given at home by a visiting nurse, with most doctor visits done remotely via video call. It involves patients with non-small cell lung cancer who are eligible for the drug atezolizumab. T…

This study is comparing two standard ways to treat small lung tumors: a minimally invasive procedure that uses microwave energy to heat and destroy the tumor, and a small surgery to cut it out. Researchers want to see which method is safer, more effective at keeping the cancer fr…

This early-stage study is testing whether two immunotherapy drugs (ipilimumab and nivolumab) can be safely combined with radiation therapy for patients with stage II or III non-small cell lung cancer. The goal is to see if this combination helps the immune system attack the cance…

This study is testing whether the immunotherapy drug pembrolizumab can prevent lung cancer in people at high risk. It includes people with suspicious lung nodules that haven't grown or shrunk, and people who've had early-stage lung cancer treated before. Participants receive the …

This study is testing a simple conversation tool designed to help people with lung cancer better understand their treatment options and participate in decisions with their doctors. The tool is being evaluated at two cancer centers with 98 participants who have non-small cell lung…

This study is testing a telehealth program designed to help people who have finished treatment for early-stage lung or colorectal cancer. It compares a special coaching program that teaches self-management skills to standard educational materials. The goal is to see if the coachi…

This study is testing an online support program designed to help women with lung cancer feel better emotionally and manage their symptoms. Participants are assigned to either a group learning mindfulness and coping skills or a group receiving educational information about lung ca…

This study aims to create a tool to predict which cancer patients are most likely to develop nerve damage (like tingling or numbness in hands and feet) from a common class of chemotherapy drugs called taxanes. Researchers will follow over 1,300 patients with breast, lung, or ovar…